Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention - Gilead Sciences
- Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention Gilead Sciences
- Gilead’s HIV prevention treatment found 100% effective in late-stage trial MarketWatch
- Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial CNBC
- Gilead's long-acting HIV drug superior to daily pill Truvada in study Reuters
- Gilead Shot Prevents 100% of HIV Cases in Trial of African Women Yahoo Finance